Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Oct 13, 2023 (filed on Oct 16, 2023)Insider Name:Puissance Capital Management LPOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,076,841Price:$0.10
-
Jun 07, 2023 (filed on Jun 07, 2023)Insider Name:Puissance Life Science Opportunities Fund VIOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-134,421Price:$0.83
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Amin NaseemOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:47,578Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Fernandes PeterOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-100,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Shah Parag SureshOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Dekker MartinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Bruder Scott POwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Kim BobaeOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Wang Theodore TOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Cloyd Mary AnnOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
Filings by filing date
-
Oct 13, 2023 (filed on Oct 16, 2023)Insider Name:Puissance Capital Management LPOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,076,841Price:$0.10
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Amin NaseemOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:47,578Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Fernandes PeterOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-100,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Shah Parag SureshOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Dekker MartinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Bruder Scott POwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Kim BobaeOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-50,000Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Wang Theodore TOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Cloyd Mary AnnOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
-
Jun 07, 2023 (filed on Jun 09, 2023)Insider Name:Teufel CrispinOwnership Type:Direct OwnershipSecurities:Stock Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-14,607Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 184 Liberty Corner Road, Suite 302 WARREN NJ 07059 |
Tel: | N/A |
Website: | www.bellerophon.com |
IR: | See website |
Key People | ||
Craig R. Jalbert President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Company Secretary, Director | Bobae Kim Vice President - Regulatory Affairs and Quality Assurance |
Business Overview |
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company's focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company's INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company's subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. |
Financial Overview |
For the nine months ended 30 September 2023, Bellerophon Therapeutics Inc revenues increased from $0K to $5.6M. Net loss decreased 71% to $4.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 53% to $5.8M (expense), Interest income increase from $67K to $296K (income). |
Employees: | 18 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $5.64M as of Sep 30, 2023 |
EBITDA (TTM): | -$11.03M as of Sep 30, 2023 |
Net annual income (TTM): | -$9.25M as of Sep 30, 2023 |
Free cash flow (TTM): | -$12.34M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 12,232,648 as of Nov 10, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |